Latest news from OHE
The Virtual ISPOR Europe 2020 will be commencing next week. A number of OHE researchers will be in attendance to present their research. With the theme Improving Health: Establishing Incentives and Sharing Value, Virtual ISPOR Europe 2020 will question the fundamental conventions around value, risk, rewards, and the role of public and private sectors.
Posted: November 10, 2020, 2:52 pm
As the world is figuring out how to deal with COVID-19, it is worth taking stock of the broader value that existing vaccines bring to societies suffering from this pandemic. We illustrate this broader value by considering how existing vaccines can help protect people from other respiratory conditions or from COVID-19 co-infections and relieve overburdened healthcare systems.
Author: Lotte Steuten, Eleanor Bell & Margherita Neri
Posted: October 8, 2020, 10:42 am
Case studies explored more and less successful practices when delivering healthcare across four priority areas (screening, disease management and standardised patient pathways, rational use of medicines and healthcare associated infections). Results were used to simulate cost-savings and patient outcomes that could potentially be realised with improvements in efficiency across the European Unio...
Author: Maria Errea, Chris Skedgel and Grace Hampson
Posted: October 6, 2020, 4:15 pm
In the focus on US drug prices, ICER has contributed thinking on determining when price aligns with patient benefits. Less debated is whether insurance coverage provides patients with fair access to a drug with a fair, value-based price. But how do we define fair access? This paper from ICER and OHE authors develops a fair access framework, proposing Ethical Goals for Access and Fair Design Cri...
Author: Adrian Towse
Posted: September 30, 2020, 1:14 pm
The inclusion of productivity value in the appraisal of health technologies is a subject of ongoing debate. In this blog, we discuss the potential impact of not considering productivity costs in the evaluation of vaccination programmes in the UK.
Author: Simon Brassel, Margherita Neri & Lotte Steuten
Posted: September 17, 2020, 10:37 am
Berdud, Drummond and Towse (2020) propose a method for establishing a reasonable price for an orphan drug. Assuming prices for drugs are set according to incremental value, they propose adjustments to a payer’s ‘normal’ cost-effectiveness threshold (CET) for non-orphan drugs to ensure orphan drug developers achieve no more than the industry-wide rate of return. Adjustments are calculated for di...
Author: Mikel Berdud and Adrian Towse
Posted: September 11, 2020, 2:25 pm
Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?
In a recently published OHE Consulting Report, we report the long-term return on investment (ROI) per £1 spent on various vaccination programmes from the perspective of the UK government. In this blog, we discuss how discounting affects the estimated long-term value of vaccination and, thus, decision-makers’ investment decisions.
Author: Simon Brassel & Lotte Steuten
Posted: August 4, 2020, 3:42 pm
This year’s OHE lecture addressed the question: how should the world pay for a COVID-19 vaccine? The paper by Adrian Towse and Isobel Firth accompanying the lecture is now published. It builds on work undertaken with Kalipso Chalkidou, Rachel Silverman and Ganesh Ramakrishnan from the Center for...
Author: Adrian Towse, Isobel Firth
Posted: July 31, 2020, 7:12 am
OHE publishes a report quantifying the level of patient access associated with NICE ‘optimised’ recommendations.
Author: Amanda Cole and Mehmet Bulut
Posted: July 30, 2020, 1:03 pm
This year’s OHE lecture addresses the question: how should the world pay for a COVID-19 vaccine? Adrian Towse, Emeritus Director of OHE and Senior Research Fellow presents the challenges that we face in developing a COVID-19 vaccine, and suggests a mechanism for buying the vaccine on a global scale.
Author: Adrian Towse and Isobel Firth
Posted: June 25, 2020, 11:24 am